Key result
Anticoagulation alone for intermediate-high-risk PE is linked to ~1-2% 7-day mortality and ~5-10% clinical deterioration.
Why the study?
Optimal management of intermediate-high-risk acute PE remains debated, and this study examined the prevalence of HI-PEITHO-eligible patients in the RIETE registry and simulated population-level projections for ultrasound-facilitated catheter-directed fibrinolysis.
Observational
Answers are grounded in this paper and cite their sources.
Registry projections may guide future trial enrollment in intermediate-high-risk PE; leaves open whether catheter-directed fibrinolysis improves outcomes.
Extract Normotensive acute pulmonary embolism (PE) with right ventricular (RV) dysfunction and elevated cardiac biomarkers (ESC intermediate-high risk; AHA/ACC categories C3–D2) is associated with a substantial risk of adverse outcomes. [1, 2] Reported 7-day mortality ranges from 1–2%, while clinical deterioration requiring escalation of care occurs in approximately 5–10% of patients treated with anticoagulation alone. [3, 4] Addressing the longstanding debate regarding the optimal management of intermediate-high-risk PE, the recently published Higher-Risk Pulmonary Embolism Thrombolysis (HI-PEITHO) trial enrolled a risk-enriched cohort with features of cardiorespiratory compromise.
No takes yet. Share an insight, caveat, or question.
Chopard et al. (2026) conducted an observational in Normotensive acute pulmonary embolism with right ventricular dysfunction and elevated cardiac biomarkers (intermediate-high risk). Ultrasound-facilitated catheter-directed fibrinolysis vs. Anticoagulation alone was evaluated. Anticoagulation alone in intermediate-high-risk pulmonary embolism is associated with 1-2% 7-day mortality and 5-10% clinical deterioration requiring care escalation.
Synapse has enriched 10 related papers. Consider them for comparative context: